Concord Drugs (BOM:538965) EPS (Basic): ₹0.94 (TTM As of Mar. 2026)

What is Concord Drugs EPS (Basic)?

Concord Drugs BOM:538965 -0.11% 57 EPS (Basic) is ₹0.94 as of Mar. 2026. GuruFocus rates BOM:538965 with a GF Score™ of 57/100 and a GF Value™ of ₹60.38 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Concord Drugs's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹0.47. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.94.

Concord Drugs's EPS (Diluted) for the three months ended in Mar. 2026 was ₹0.47. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.94.

Concord Drugs's EPS without NRI for the three months ended in Mar. 2026 was ₹0.47. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.94.

During the past 12 months, Concord Drugs's average EPS without NRIGrowth Rate was 179.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -3.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -16.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Concord Drugs's highest 3-Year average EPS without NRI Growth Rate was 73.00% per year. The lowest was -61.60% per year. And the median was -3.15% per year.

Concord Drugs (BOM:538965) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Concord Drugs EPS (Basic) Related Terms

Concord Drugs EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Concord Drugs's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs EPS (Basic) Chart

Concord Drugs Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

EPS (Basic)

Get a 7-Day Free Trial

1.82

1.06

0.47

0.34

0.95

Concord Drugs Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															0.04	0.12	0.19	0.16	0.47

57GF Score

Concord Drugs Ltd BOM:538965

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Concord Drugs EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Concord Drugs's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(10.55	-	0)	/	11.105
	=	0.95

Concord Drugs's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(5.28	-	0)	/	11.234
	=	0.47

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.94

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of ₹0.94 mean?

Concord Drugs (BOM:538965) has a EPS (Basic) of ₹0.94 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Concord Drugs and its competitors.

Is Concord Drugs' EPS (Basic) too high?

Concord Drugs' current EPS (Basic) is ₹0.94. Overall, Concord Drugs has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Concord Drugs' EPS (Basic) compare to ZTS?

Concord Drugs' EPS (Basic) of ₹0.94 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Drug Manufacturers company?

A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Concord Drugs and its competitors. Concord Drugs's current EPS (Basic) is ₹0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Concord Drugs stock overvalued right now?

Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.38, compared to a current price of ₹76.05 — trading 26% above its estimated fair value. The current EPS (Basic) is ₹0.94. Concord Drugs' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current EPS (Basic) is ₹0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹76.05 is trading 26% above its estimated GF Value™ of ₹60.38. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

EPS (Basic): ₹0.94
GF Value™: ₹60.38 vs. price of ₹76.05 (26% above fair value)
GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Drugs Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NSE:PAR BOM:524572 BOM:537536 BOM:506919 NSE:CURIS NSE:SOTAC BOM:538964 BOM:530317 NSE:ZENITHDRUG BOM:524518 XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511

Website https://www.concorddrugs.in

Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.

57GF Score

Get the complete analysis for BOM:538965

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹76.05

Price

₹60.38

GF Value

View BOM:538965 Analysis

See EPS (Basic) data for all stocks →